May 15,2024

Innovate UK funds digital health compliance platform

Innovate UK has awarded Naq £322,000($405,932) to enhance its digital health compliance platform, aiming to streamline the compliance process for digital health technologies in the NHS. Naq’s platform automates compliance work, saving time and resources by providing real-time visibility into compliance status across various standards. This project addresses the time-consuming and resource-intensive requirements for Digital Technology Assessment Criteria (DTAC) approval necessary for NHS adoption. Naq, based in London and Amsterdam, also raised €3m in seed funding earlier this year to further its mission.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Mar 13,2024

Proscia’s $46M Series C propels AI-driven pathology into the mainstream

Proscia, a leading provider of digital pathology software, announced today that it has raised $9 million in an extension of its Series C funding round, bringing the total round to $46 million. The funding comes on the heels of Proscia’s recent FDA clearance for its software platform, enabling the company to expand its reach in the U.S. diagnostic market. The Series C extension was led by Highline Capital Management and Triangle Peak Partners, with participation from existing investors including Alpha Intelligence Capital, Scale Venture Partners, Hitachi Ventures, and others. The funds will be used to accelerate Proscia’s commercial growth and further develop its AI-powered applications for life sciences and diagnostic laboratories.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Mar 15,2024 TOP STORY

Sugar.fit Receives $5M in Series A Funding

Diabetes-focused health tech startup Sugar.fit has received an additional $5 million in Series A funding from B Capital. This brings its total Series A funding, the first round of which occurred in November, to $16 million. In a statement, the company said it will use its additional funds to expand its offerings, increase its presence, and hasten R&D in diabetes management. Sugar.fit has also recently started operating diabetes clinics in Bangalore, which offer a range of services such as stress therapies, live fitness and yoga sessions, and VR chromotherapy.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Feb 27,2024 TOP STORY

Hedia Raises €3M Seed Extension to Expand Digital Health Portfolio

Hedia announced this week it has raised €3 million in a seed extension round strongly supported by existing shareholders and Business Angels. The new capital will enable Hedia's growth strategy and promising digital health product roadmap, continue to scale their Hedia Diabetes Assistant (HDA), as well as launching the Glooko- integrated holistic diabetes management solution later in the year.  Furthermore, the company will leverage its competencies in developing smart AI-enabled algorithms and Software-as-a-Medical Device (SaMD) solutions together with strategic partners within chronic metabolic diseases.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Feb 22,2024 TOP STORY

New Challenger Onboard? Syai Health Brings the New Fashion to CGM Experience & Chronic Disease Management

Singapore-based biotech company, Syai Health, abbreviated for "Sychronise + AI", secured significant funding from leading investors like AstraZeneca plc and Xiaomi Corporation for its in-house developed AI-empowered medical devices. Syai Health is prepared to broaden the horizon and reshape the CGM experience with its user-centric product lineup empowered by AI integration. Syai's CGM device pairs with a user-friendly app and cloud-based data solutions that allow patients to track, retrieve, and share real-time data or reports with their healthcare providers or families for more comprehensive care.

FUNDING FUNDING ROUND

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 16,2021

Resilience Raises €5M To Accelerate the Development of Its Remote Patient Monitoring Platform in Oncology

Resilience is a new startup wants to help cancer treatment institutes as well as cancer patients at every step of the treatment journey. They recently raised a $6 million funding round (€5 million) led by Singular, the VC firm founded by former Alven partners Raffi Kamber and Jérémy Uzan. Tech business angels Nathalie Balla (La Redoute), Xavier Niel (Free), Jean-Charles Samuelian (Alan), Roxanne Varza (Station F) and more are also participating. There are also some healthcare investors in today’s funding round, such as Charles Ferté (AstraZeneca), Philippe Dabi (Bioclinic) and Thomas Clozel (Owkin). Resilience wants to become a full-stack software solution for cancer treatment for both the medical team and patients. When it comes to practitioners, Resilience will be a software-as-a-service solution that can augment therapeutic decisions. When it comes to patients, there will be a web and mobile app to access content and information about their cancer. In particular, Resilience could help you understand side effects and treat them.

FUNDING SEED ROUND

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 25,2022

French Healthtech Resilience Raises €40 Million to Improve the Care Pathway for Cancer Patients

After a €5M financing in 2021, Resilience announces a €40M Series A round led by the global investment firm Cathay Innovation with strong support from the French VC Singular. Three European funds: Exor Seeds, Picus Capital and Seaya Ventures are also participating in the round as well as a consortium of healthcare players: Fondation Santé Service, MACSF, Ramsay Santé and Vivalto Ventures. This funding will allow the company to accelerate the deployment of its medical devices (CE Class IIa) in healthcare institutions and to enrich its application with new functionalities dedicated to the well-being of patients. Co-founded less than a year ago by two tech entrepreneurs, Céline Lazorthes and Jonathan Benhamou, in partnership with the Gustave Roussy Institute, the 5th largest cancer center in the world, Resilience’s mission is to reinvent the way we treat cancer through digital and remote medical monitoring.

FUNDING SERIES A

#rpm

View Analyst & Ambassador Comments
Go to original news
Feb 01,2024 TOP STORY

ArteraAI Raises $20M to Personalize Cancer Therapy With Multimodal AI

ArteraAI, a pioneer in multi-modal artificial intelligence (MMAI) for cancer treatment personalization, announced today an additional $20M in funding. This latest round, backed by prominent investors like Prosperity7 Ventures, EDBI, and Wilson Sonsini Goodrich & Rosati, brings the company’s total funding to $110M since its inception less than a year ago. ArteraAI’s MMAI platform analyzes digital pathology images and clinical data to deliver accurate predictions about cancer progression and response to treatment. This information empowers clinicians to make more informed decisions about personalized treatment plans, potentially improving patient outcomes and reducing unnecessary procedures. The company also offers an AI-enabled Prostate test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer/ ArteraAI’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient’s clinical data. 

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 29,2024 TOP STORY

Cognito Therapeutics raises $35M Series B extension

Obviously there's no known cure for Alzheimer’s right now but Cognito Therapeutics is looking to finally find one with its medical device that delivers both visual and auditory stimulation for the treatment for Alzheimer’s, and other neurodegenerative diseases. The company announced an extension of the Series B round they raised $73 million in March 2023 from FoundersX, Morningside, Alzheimer’s Drug Discovery Foundation, IAG Capital, Starbloom, WSGR; this brings the total round to $108 million and its total funding to $128 million. Since raising its last funding, Cognito started its Ph3/Pivotal study for the treatment of Alzheimer’s Disease, called HOPE, which has over 250 patients enrolled so far. "We have made great progress with study enrollment. We expect to have the study fully enrolled this summer with top-line readout and FDA submission expected in 2H 2025," Brent Vaughan, CEO of Cognito Therapeutics, told.

FUNDING SERIES B

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 01,2024

Mesh Bio bags $3.5M to bring digital twin tech to Hong Kong, Indonesia, Philippines

Singaporean startup Mesh Bio has raised $3.5 million in a Series A funding round led by East Ventures. The round was also participated by Elev8, Seed Capitals, and its other shareholders. Mesh Bio has a targeted focus on both Indonesia and the Philippines where chronic diseases are said to be most prevalent and deadly. In a statement, the company said it will use its fresh funds to scale the deployment of its solutions, particularly its flagship digital twin offering, across Hong Kong and Southeast Asia. The latest funding raise comes three months after Mesh Bio secured a regulatory clearance from Singapore’s Health Sciences Authority for HealthVector Diabetes. The digital twin-based software-as-a-medical device can predict a 3-year onset risk of chronic kidney disease in patients with type 2 diabetes by using clinical data pulled from hospital EMRs. The digital twin solution, which is an expanded offering on Mesh Bio's DARA Health Intelligence Platform, is now being trialled at Singapore General Hospital, Tan Tock Seng Hospital, and selected polyclinics in Singapore.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING